Elite Pharmaceuticals, Inc. (ELTP) Operating margin 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) operating margin by fiscal year — reported operating income divided by reported revenue.
33.0%FY2026 · since FY2017: -76.3% → 33.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 33.0% | +9.7 pp |
| FY2025 | 23.3% | +4.3 pp |
| FY2024 | 19.1% | +8.3 pp |
| FY2023 | 10.8% | -5.0 pp |
| FY2022 | 15.7% | +7.4 pp |
| FY2021 | 8.3% | +21.0 pp |
| FY2020 | -12.7% | +108.3 pp |
| FY2019 | -121.0% | +0.3 pp |
| FY2018 | -121.4% | -45.0 pp |
| FY2017 | -76.3% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net incomeELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →